Comparison Between Gleason Score and Apparent Diffusion Coefficient Obtained from Diffusion-Weighted Imaging of Prostate Cancer Patients

REFERENCES

• Kundra V, Silverman PM, Matin SF, Choi H. Imaging in oncology from the University of Texas M.D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. Am J Roentgenol 2007;189:830–844.
   PubMed Web of Science ®Google Scholar
• Boscaino A, Di Costanzo G, Giovagnoni A, Maggioni F, Ragozzino A, Regine R, Carcinoma della prostata. Risonanza magnetica: l'essenziale.
   Google Scholar
• Schröder FH, Jonas Hugosson J, Roobol MJ, Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–990.
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. Am J Roentgenol 2009;192:1455–1470.
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730–733.
   PubMed Web of Science ®Google Scholar
• Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18:71–77.
   PubMed Web of Science ®Google Scholar
• Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12:2294–2302.
   PubMed Web of Science ®Google Scholar
• Caivano R, Cirillo P, Balestra A, Lotumolo A, Fortunato G, Macarini L, Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences. J Med Imag Radiat Oncol 2012;56(6):606–616.
   PubMed Web of Science ®Google Scholar
• Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, MR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (1H) MR spectroscopy in comparison with histology radiology research and practice volume. Radiol Res Pract 2011;2011:616852.
   Google Scholar
• Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012;2012:374805.
   PubMedGoogle Scholar
• Kagebayashi Y, Nakai Y, Matsumoto Y, Samma S, Miyasaka T, Nakagawa H. Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score. Hinyokika Kiyo 2012;58:405–408.
   PubMedGoogle Scholar
• Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012;22:1812–1819.
   PubMed Web of Science ®Google Scholar
• Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El-Ghar M. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. Sci World J 2012;2012:973450.
   Google Scholar
• Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol 2012;47:153–158.
   PubMed Web of Science ®Google Scholar
• Cornud F, Delongchamps NB, Mozer P, Beuvon F, Schull A, Muradyan N, Peyromaure M. Value of multiparametric MRI in the work-up of prostate cancer. Curr Urol Rep 2012;13:82–92.
   PubMed Web of Science ®Google Scholar
• Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol 2011;197:1382–1390.
   PubMed Web of Science ®Google Scholar
• Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol 2010;194:316–322.
   PubMed Web of Science ®Google Scholar
• Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, van Oort I, Schröder F, Huisman H, Barentsz J. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:177–184.
   PubMed Web of Science ®Google Scholar
• Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006;23:130–134.
   PubMed Web of Science ®Google Scholar
• Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259(2):453–461.
   PubMed Web of Science ®Google Scholar
• Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, Tanimoto D, Apparent diffusion coefficient values in peripheral and transition zones of prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Res Imag 2008;28:720–726.
   PubMed Web of Science ®Google Scholar
• Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007;189:323–328.
   PubMed Web of Science ®Google Scholar
• Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174:2158–2163.
   PubMed Web of Science ®Google Scholar
• Kim JK, Jang YJ, Cho G. Multidisciplinary functional MR Imaging for Prostate Cancer. Korean J Radiol 2009;10:535–551.
   PubMed Web of Science ®Google Scholar
• Kim CK, Park BK, Kim B. High b-Value Diffusion-weighted imaging at 3T to detect prostate cancer: Comparisons between b value of 1000 and 2000 s/mn2. Am J Roentgenol 2010;194:33–37.
   PubMed Web of Science ®Google Scholar
• Kitajima K, Kaji Y, Kuroda K, Sugimura K. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci 2008;7:93–99.
   PubMedGoogle Scholar
• Bentzen S. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112–117.
   PubMed Web of Science ®Google Scholar
• Pedicini P, Strigari L, Benassi M. Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2013;85(5):231–237.
   Google Scholar
• Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V. In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2013;85(1):10–11.
   PubMedGoogle Scholar
• Pedicini P. Kick-off time for accelerated cell repopulation during the radiotherapy: the hypothesis of stem-cells. Int J Radiat Oncol Biol Phys 2013. DOI: 10.1016/j.ijrobp.2013.08.016.
   Google Scholar